According to Genocea Biosciences
's latest financial reports the company has a price-to-book ratio of 0.0005.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 0.0005 | -99.98% |
2021-12-31 | 2.46 | -82.31% |
2020-12-31 | 13.9 | 513.05% |
2019-12-31 | 2.27 | -33.11% |
2018-12-31 | 3.39 | -161.65% |
2017-12-31 | -5.50 | -314.34% |
2016-12-31 | 2.57 | 55.17% |
2015-12-31 | 1.65 | -56.96% |
2014-12-31 | 3.84 | |
2013-12-31 | N/A | |
2012-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Pfizer PFE | 1.76 | 370,706.52% | ๐บ๐ธ USA |
Merck MRK | 8.88 | 1,870,830.84% | ๐บ๐ธ USA |
Novavax NVAX | -0.9331 | -196,708.34% | ๐บ๐ธ USA |
Agenus
AGEN | -1.64 | -345,120.92% | ๐บ๐ธ USA |
iBio IBIO | 1.54 | 323,985.66% | ๐บ๐ธ USA |